Identification of potent and selective RNA antagonists of the IFN-γ-inducible CXCL10 chemokine

被引:19
|
作者
Marro, ML
Daniels, DA
McNamee, A
Andrew, DP
Chapman, TD
Jiang, MS
Wu, ZN
Smith, JL
Patel, KK
Gearing, KL
机构
[1] GlaxoSmithKline, Med Res Ctr, Gene Expression & Prot Biochem, Stevenage SG1 2NY, Herts, England
[2] GlaxoSmithKline, Med Res Ctr, Computat Analyt & Struct Sci, Stevenage SG1 2NY, Herts, England
[3] GlaxoSmithKline, Med Res Ctr, Immunopharmacol & Screening Sci, Stevenage SG1 2NY, Herts, England
[4] GlaxoSmithKline, Dept Assay Dev & Cmpd Profiling, King Of Prussia, PA 19406 USA
关键词
D O I
10.1021/bi048145w
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CXCL10 (also known as IP-10 in humans and CRG-2 in mice) is a nonglycosylated chemokine and a member of the non-ELR CXC chemokine subfamily implicated in a variety of inflammatory conditions. The role of CXCL10 in different disease states still requires clarification, and new approaches are necessary to better understand its biological function. We report here the isolation of a series of nuclease-resistant RNA aptamers that act to antagonize human CXCL10 function in a number of in vitro and cell-based assays. The two most potent aptamers identified were highly selective for human CXCL10. A further aptamer was identified that antagonized both the human and the mouse CXCL10. A combination of a molecular-biology-based truncation and solid-phase synthesis enabled the truncation of one of the aptamers from 71 to 34 nucleotides. This was followed by PEGylation, 3' capping, and further stabilization of the RNA aptamer, while its high potency was maintained. These aptamers could be utilized as powerful target validation tools and may also have therapeutic potential. To our knowledge, the CXCL 10 aptamers generated are the most potent antagonists of CXCL10/CXCR3 signaling reported to date.
引用
收藏
页码:8449 / 8460
页数:12
相关论文
共 50 条
  • [41] IFN-inducible protein 10 (CXCL10) regulates tubular cell proliferation in renal ischemia-reperfusion injury
    Furuichi, Kengo
    Wada, Takashi
    Kitajikma, Shinji
    Toyama, Tadasi
    Okumura, Toshiya
    Hara, Akinori
    Kawachi, Hiroshi
    Shimizu, Fujio
    Sugaya, Takeshi
    Mukaida, Naofumi
    Narumi, Shosaku
    Matsushima, Kouji
    Kaneko, Shuichi
    NEPHRON EXPERIMENTAL NEPHROLOGY, 2008, 109 (01): : C29 - C38
  • [42] Plasmacytoid Dendritic Cells Depletion and Elevation of IFN-γ Dependent Chemokines CXCL9 and CXCL10 in Children With Multisystem Inflammatory Syndrome
    Caldarale, Francesca
    Giacomelli, Mauro
    Garrafa, Emirena
    Tamassia, Nicola
    Morreale, Alessia
    Poli, Piercarlo
    Timpano, Silviana
    Baresi, Giulia
    Zunica, Fiammetta
    Cattalini, Marco
    Moratto, Daniele
    Chiarini, Marco
    Cannizzo, Elvira Stefania
    Marchetti, Giulia
    Cassatella, Marco Antonio
    Taddio, Andrea
    Tommasini, Alberto
    Badolato, Raffaele
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [43] TNFSF14 coordinately enhances CXCL10 and CXCL11 productions from IFN-γ-stimulated human gingival fibroblasts
    Hosokawa, Yoshitaka
    Hosokawa, Ikuko
    Ozaki, Kazumi
    Nakae, Hideaki
    Matsuo, Takashi
    MOLECULAR IMMUNOLOGY, 2010, 47 (04) : 666 - 670
  • [44] Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine
    Swaminathan, GJ
    Holloway, DE
    Colvin, RA
    Campanella, GK
    Papageorgiou, AC
    Luster, AD
    Acharya, KR
    STRUCTURE, 2003, 11 (05) : 521 - 532
  • [45] CXCL10 (IFN-γ-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis
    Fife, BT
    Kennedy, KJ
    Paniagua, MC
    Lukacs, NW
    Kunkel, SL
    Luster, AD
    Karpus, WJ
    JOURNAL OF IMMUNOLOGY, 2001, 166 (12): : 7617 - 7624
  • [46] Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma
    Teichmann, M
    Meyer, B
    Beck, A
    Niedobitek, G
    JOURNAL OF PATHOLOGY, 2005, 206 (01): : 68 - 75
  • [47] SLAMF7 Is a Critical Negative Regulator of IFN-α-Mediated CXCL10 Production in Chronic HIV Infection
    O'Connell, Patrick
    Pepelyayeva, Yuliya
    Blake, Maja K.
    Hyslop, Sean
    Crawford, Robert B.
    Rizzo, Michael D.
    Pereira-Hicks, Cristiane
    Godbehere, Sarah
    Dale, Linda
    Gulick, Peter
    Kaminski, Norbert E.
    Amalfitano, Andrea
    Aldhamen, Yasser A.
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01): : 228 - 238
  • [48] Chemokine CXCL10 gene polymorphisms are associated with type 1 diabetes
    Ramos-Lopez, E.
    Bartsch, W.
    Brueck, P.
    Kahles, H.
    Penna-Martinez, M.
    Herwig, J.
    Badenhoop, K.
    DIABETOLOGIA, 2007, 50 : S133 - S134
  • [49] Toxicity and Structure of Antimicrobial Peptides Derived from the Chemokine, CXCL10
    Bailer, Peter
    Ward, Amanda E.
    Crawford, Matthew
    Fisher, Debra
    Tamm, Lukas K.
    Hughes, Molly
    BIOPHYSICAL JOURNAL, 2019, 116 (03) : 83A - 83A
  • [50] Pathogen Evasion of Chemokine Response Through Suppression o CXCL10
    Antonia, Alejandro L.
    Gibbs, Kyle D.
    Trahair, Esme D.
    Pittman, Kelly J.
    Martin, Amelia T.
    Schott, Benjamin H.
    Smith, Jeffrey S.
    Rajagopal, Sudarshan
    Thompson, J. Will
    Reinhardt, Richard Lee
    Ko, Dennis C.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9